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Background
Phosphodiesterase 5 (PDE5) is associated with migraine
pathophysiology, stroke recovery and vasospasm treat-
ment [1,2]. We have shown previously that vasodilata-
tion was not a prerequisite for migraine induction;
sildenafil elicited migraine-like attacks in migraine
patients without measurable changes in intra- or extra-
cerebral artery diameter. Further, sildenafil was found to
not affect neurovascular response or excitability [3].
However, dural artery responses were not accounted for
in the human studies and minor vascular changes of
functional importance may not have been detected.
The potential vascular interplay of PDE5 inhibitors sil-
denafil, tadalafil and UK-114,542 were studied by intra-
versus extra-luminal administration in rat middle cere-
bral arteries (MCA) in vitro and on middle meningeal
arteries (MMA) in vivo.
Aim
To examine a possible vascular site of action, if any, of
each of sildenafil and tadalafil by investigating 1) the
effects of PDE5 inhibitors in vitro dilatation of the mid-
dle cerebral artery (MCA) with controlled luminal or
extra-luminal application of the drugs and 2) the in vivo
effects of intravenous PDE5 inhibitors on the middle
meningeal artery (MMA) dilatation in a closed cranial
window model in rats.
Methods
Rat MCA diameter was investigated using pressurised
arteriography, applying UK-114,542, sildenafil, and
tadalafil intra- or extra-luminally. Effects on MMA were
studied in the in vivo closed cranial window model.
Results
At high concentrations, abluminal sildenafil and UK-
114,542, but not tadalafil, induced dilatation. Luminal
application elicited a contraction of 4 % (sildenafil, p =
0.03) and 10 % (tadalafil, p = 0.02). In vivo, sildenafil,
but not tadalafil, dose-dependently dilated MMA conco-
mitant to blood pressure reduction (1-3 mg/kg);1 mg/kg
sildenafil inducing 60 ± 14 % (p = 0.04) and vehicle
(DMSO) 13 ± 6 % dilatation.
Conclusion
PDE5 inhibitors applied luminally had contractile effect
on MCA. Abluminal sildenafil induced MCA dilatation
above therapeutic levels. In vivo, sildenafil dilated MMA.
Tadalafil had no dilatory effects. PDE5 inhibitors show
differential vascular activity in arteries, although clini-
cally the potential for headache induction appears simi-
lar. Such findings support clinical studies showing no
vasodilatory effects of sildenafil on cerebral arteries in
healthy subjects.
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